Strategic expansion Velocity Pharma has launched Primacure Ventures to develop 8–10 prescription oral solid dosage products, indicating a shift toward higher-margin Rx partnerships and potential co-development or private-label opportunities with hospital and specialty pharmacies.

Private-label strength With a focus on private-label over-the-counter products for top global retail chains and a diverse dosage form portfolio, there is an opportunity to expand private-label collaborations, especially for new OTC lines and reformulations.

Regulatory risk Recent FDA-related eye drop recalls and associated voluntary recalls via Cardinal Health suggest quality control and regulatory diligence as a critical buyer concern; presenting robust GMP, QA, and traceability improvements can build trust with distributors and retailers.

Distribution partnerships Existing partnership with Cardinal Health presents a pathway for expanded distribution, cross-sell of both OTC and potential Rx lines, and co-marketing opportunities to reach large retail networks and eye care channels.

Tech enabled selling A lean team with a global supply focus and a tech stack including digital advertising and CRM-ready tools indicates readiness for targeted sales campaigns, data-driven outreach, and lead generation for new product launches.